179 related articles for article (PubMed ID: 32955139)
1. Linker Hydrophilicity Modulates the Anticancer Activity of RGD-Cryptophycin Conjugates.
Anselmi M; Borbély A; Figueras E; Michalek C; Kemker I; Gentilucci L; Sewald N
Chemistry; 2021 Jan; 27(3):1015-1022. PubMed ID: 32955139
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Characterization of Monomeric and Tetrameric RGD-Cryptophycin Conjugates.
Borbély A; Thoreau F; Figueras E; Kadri M; Coll JL; Boturyn D; Sewald N
Chemistry; 2020 Feb; 26(12):2602-2605. PubMed ID: 31943410
[TBL] [Abstract][Full Text] [Related]
3. Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies.
Lai Q; Wu M; Wang R; Lai W; Tao Y; Lu Y; Wang Y; Yu L; Zhang R; Peng Y; Jiang X; Fu Y; Wang X; Zhang Z; Guo C; Liao W; Zhang Y; Kang T; Chen H; Yao Y; Gou L; Yang J
Eur J Med Chem; 2020 Aug; 199():112364. PubMed ID: 32402935
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
5. Conjugates of Cryptophycin and RGD or
Borbély A; Figueras E; Martins A; Bodero L; Raposo Moreira Dias A; López Rivas P; Pina A; Arosio D; Gallinari P; Frese M; Steinkühler C; Gennari C; Piarulli U; Sewald N
ChemistryOpen; 2019 Jun; 8(6):737-742. PubMed ID: 31275795
[TBL] [Abstract][Full Text] [Related]
6. Reductively cleavable polymer-drug conjugates based on dendritic polyglycerol sulfate and monomethyl auristatin E as anticancer drugs.
Rades N; Achazi K; Qiu M; Deng C; Haag R; Zhong Z; Licha K
J Control Release; 2019 Apr; 300():13-21. PubMed ID: 30794827
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biological Evaluation of RGD and isoDGR-Monomethyl Auristatin Conjugates Targeting Integrin α
Raposo Moreira Dias A; Bodero L; Martins A; Arosio D; Gazzola S; Belvisi L; Pignataro L; Steinkühler C; Dal Corso A; Gennari C; Piarulli U
ChemMedChem; 2019 May; 14(9):938-942. PubMed ID: 30840356
[TBL] [Abstract][Full Text] [Related]
8. RGD Peptidomimetic MMAE-Conjugate Addressing Integrin αVβ3-Expressing Cells with High Targeting Index.
Paulus J; Nachtigall B; Meyer P; Sewald N
Chemistry; 2023 Feb; 29(12):e202203476. PubMed ID: 36454662
[TBL] [Abstract][Full Text] [Related]
9. Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugation.
Yang K; Chen B; Gianolio DA; Stefano JE; Busch M; Manning C; Alving K; Gregory RC; Brondyk WH; Miller RJ; Dhal PK
Org Biomol Chem; 2019 Sep; 17(35):8115-8124. PubMed ID: 31460552
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of RGD⁻Cryptophycin Conjugates for Targeted Drug Delivery.
Borbély A; Figueras E; Martins A; Esposito S; Auciello G; Monteagudo E; Di Marco A; Summa V; Cordella P; Perego R; Kemker I; Frese M; Gallinari P; Steinkühler C; Sewald N
Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30939768
[TBL] [Abstract][Full Text] [Related]
11. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
12. β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate.
López Rivas P; Müller C; Breunig C; Hechler T; Pahl A; Arosio D; Belvisi L; Pignataro L; Dal Corso A; Gennari C
Org Biomol Chem; 2019 May; 17(19):4705-4710. PubMed ID: 31020985
[TBL] [Abstract][Full Text] [Related]
13. Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Liang J; Moore RE; Moher ED; Munroe JE; Al-awar RS; Hay DA; Varie DL; Zhang TY; Aikins JA; Martinelli MJ; Shih C; Ray JE; Gibson LL; Vasudevan V; Polin L; White K; Kushner J; Simpson C; Pugh S; Corbett TH
Invest New Drugs; 2005 Jun; 23(3):213-24. PubMed ID: 15868377
[TBL] [Abstract][Full Text] [Related]
14. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
[TBL] [Abstract][Full Text] [Related]
15. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
16. Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate.
Mohamed Amar IA; Huvelle S; Douez E; Letast S; Henrion S; Viaud-Massuard MC; Aubrey N; Allard-Vannier E; Joubert N; Denevault-Sabourin C
Eur J Med Chem; 2022 Feb; 229():114063. PubMed ID: 34974337
[TBL] [Abstract][Full Text] [Related]
17. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
18. Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis.
Nahrwold M; Weiß C; Bogner T; Mertink F; Conradi J; Sammet B; Palmisano R; Royo Gracia S; Preuße T; Sewald N
J Med Chem; 2013 Mar; 56(5):1853-64. PubMed ID: 23387527
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted Conjugate.
Raposo Moreira Dias A; Pina A; Dean A; Lerchen HG; Caruso M; Gasparri F; Fraietta I; Troiani S; Arosio D; Belvisi L; Pignataro L; Dal Corso A; Gennari C
Chemistry; 2019 Feb; 25(7):1696-1700. PubMed ID: 30452790
[TBL] [Abstract][Full Text] [Related]
20. Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin α
Raposo Moreira Dias A; Pina A; Dal Corso A; Arosio D; Belvisi L; Pignataro L; Caruso M; Gennari C
Chemistry; 2017 Oct; 23(58):14410-14415. PubMed ID: 28816404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
